CHDI
Listed here are over 1,045 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Papadopoulou AS, Gomez-Paredes C, Mason MA, Taxy BA, Howland D, Bates GP
Extensive expression analysis of Htt transcripts in brain regions from the zQ175 HD mouse model using a QuantiGene multiplex assay
Irvine EE, Katsouri L, Plattner F, Al-Qassab H, Al-Nackkash R, Bates GP, Withers DJ
Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington's disease
Marottoli FM, Priego M, Flores-Barrera E, Pisharody R, Zaldua S, Fan KD, Ekkurthi GK, Brady ST, Morfini GA, Tseng KY, Tai LM
EGF treatment improves motor behavior and cortical GABAergic function in the R6/2 mouse model of Huntington's disease
Gregory S, Odish OFF, Mayer I, Mills J, Johnson EB, Scahill RI, Rothwell J, Rees G, Long JD, Tabrizi SJ, Roos RAC, Orth M
Multimodal characterization of the visual network in Huntington's disease gene carriers
Clin Neurophysiol
November 1, 2019
130 (11) :2053-2059
130 (11) :2053-2059
PMID: 31541982
Ciosi M, Maxwell A, Cumming SA, Hensman Moss DJ, Alshammari AM, Flower MD, Durr A, Leavitt BR, Roos RAC, TRACK-HD team, Enroll-HD team Holmans P, Jones L, Langbehn DR, Kwak S, Tabrizi SJ, Monckton DG
A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes
Diaz-Castro B, Gangwani MR, Yu X, Coppola G, Khakh BS
Astrocyte molecular signatures in Huntington's disease
Haremaki T, Metzger JJ, Rito T, Ozair MZ, Etoc F, Brivanlou AH
Self-organizing neuruloids model developmental aspects of Huntington's disease in the ectodermal compartment
Kim KH, Abu Elneel K, Shin JW, Keum JW, Seong D, Kwak S, Lee R, Gusella JF, MacDonald ME, Seong IS, Lee JM
Full sequence of mutant huntingtin 3'-untranslated region and modulation of its gene regulatory activity by endogenous microRNA
Poudel GR, Harding IH, Egan GF, Georgiou-Karistianis N
Network spread determines severity of degeneration and disconnection in Huntington's disease
Hum Brain Mapp
October 1, 2019
40 (14) :4192-4201
40 (14) :4192-4201
PMID: 31187915
PMCID: 6865500
DOI: 10.1002/hbm.24695
Sap KA, Guler AT, Bezstarosti K, Bury AE, Juenemann K, Demmers JAA, Reits EA
Global proteome and ubiquitinome changes in the soluble and insoluble fractions of Q175 Huntington mice brains
Khakh BS
Astrocyte-neuron interactions in the striatum: insights on identity, form, and function
van der Plas E, Langbehn DR, Conrad AL, Koscik TR, Tereshchenko A, Epping EA, Magnotta VA, Nopoulos PC
Abnormal brain development in child and adolescent carriers of mutant huntingtin
Kubera KM, Schmitgen MM, Hirjak D, Wolf RC, Orth M
Cortical neurodevelopment in pre-manifest Huntington's disease
Wanker EE, Ast A, Schindler F, Trepte P, Schnoegl S
The pathobiology of perturbed mutant huntingtin protein-protein interactions in Huntington's disease
Swainson LA, Ahn H, Pajanirassa P, Khetarpal V, Deleage C, Estes JD, Hunt PW, Munoz-Sanjuan I, McCune JM
Kynurenine 3-Monooxygenase inhibition during acute simian immunodeficiency virus infection lowers PD-1 expression and improves post-combination antiretroviral therapy CD4(+) T cell counts and body weight
Langbehn DR, Stout JC, Gregory S, Mills JA, Durr A, Leavitt BR, Roos RAC, Long JD, Owen G, Johnson HJ, Borowsky B, Craufurd D, Reilmann R, Landwehrmeyer GB, Scahill RI, Tabrizi SJ, TRACK-HD and Track-On HD Groups
Association of CAG repeats with long-term progression in Huntington disease
Federspiel JD, Greco TM, Lum KK, Cristea IM
Hdac4 interactions in Huntington's disease viewed through the prism of Multiomics
GeM-HD Consortium, Lee JM, Correia K, Loupe J, Kim KH, Barker D, Hong EP, Chao MJ, Long JD, Lucente D, Vonsattel JPG, Pinto RM, Abu Elneel K, Ramos EM, Mysore JS, Gillis T, Wheeler VC, MacDonald ME, Gusella JF, McAllister B, Massey T, Medway C, Stone TC, Hall L, Jones L, Holmans P, Kwak S, Ehrhardt AG, Sampaio C, Ciosi M, Maxwell A, Chatzi A, Monckton DG, Orth M, Landwehrmeyer GB, Paulsen JS, Dorsey ER, Shoulson I, Myers RH
CAG repeat not polyglutamine length determines timing of Huntington's disease onset
Huhtala T, Poutiainen P, Rytkönen J, Lehtimäki K, Parkkari T, Kasanen I, Airaksinen AJ, Koivula T, Sweeney P, Kontkanen O, Wityak J, Dominiquez C, Park LC
Improved synthesis of [(18)F] fallypride and characterization of a Huntington's disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors
Alterman JF, Godinho BMDC, Hassler MR, Ferguson CM, Echeverria D, Sapp E, Haraszti RA, Coles AH, Conroy F, Miller R, Roux L, Yan P, Knox EG, Turanov AA, King RM, Gernoux G, Mueller C, Gray-Edwards HL, Moser RP, Bishop NC, Jaber SM, Gounis MJ, Sena-Esteves M, Pai AA, DiFiglia M, Aronin N, Khvorova A
A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system
Gatto RG, Ye AQ, Colon-Perez L, Mareci TH, Lysakowski A, Price SD, Brady ST, Karaman M, Morfini G, Magin RL
Detection of axonal degeneration in a mouse model of Huntington's disease: comparison between diffusion tensor imaging and anomalous diffusion metrics
Kacher R, Lamazière A, Heck N, Kappes V, Mounier C, Despres G, Dembitskaya Y, Perrin E, Christaller W, Sasidharan Nair S, Messent V, Cartier N, Vanhoutte P, Venance L, Saudou F, Néri C, Caboche J, Betuing S
CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease
Bertoglio D, Verhaeghe J, Miranda A, Kertesz I, Cybulska K, Korat Š, Wyffels L, Stroobants S, Mrzljak L, Dominguez C, Liu L, Skinbjerg M, Munoz-Sanjuan I, Staelens S
Validation and noninvasive kinetic modeling of [(11) C] UCB-J PET imaging in mice
Flower M, Lomeikaite V, Ciosi M, Cumming S, Morales F, Lo K, Hensman Moss D, Jones L, Holmans P, TRACK-HD Investigators, OPTIMISTIC Consortium, Monckton DG, Tabrizi SJ
MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1
Wilkes FA, Abaryan Z, Ching CRK, Gutman BA, Madsen SK, Walterfang M, Velakoulis D, Stout JC, Chua P, Egan GF, Thompson PM, Looi JCL, Georgiou-Karistianis N
Striatal morphology and neurocognitive dysfunction in Huntington disease: the IMAGE-HD study
Psychiatry Res Neuroimaging
July 12, 2019
291 :43838
291 :43838
PMID: 31330407
Franich NR, Hickey MA, Zhu C, Osborne GF, Ali N, Chu T, Bove NH, Lemesre V, Lerner RP, Zeitlin SO, Howland D, Neueder A, Landles C, Bates GP, Chesselet MF
Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene
Shishegar R, Rajapakse S, Georgiou-Karistianis N
Altered cortical morphometry in pre-manifest Huntington's disease: Cross-sectional data from the IMAGE-HD study
Annu Int Conf IEEE Eng Med Biol
July 1, 2019
2019 :2844-2847
2019 :2844-2847
PMID: 31946485
Zeitler B, Froelich S, Marlen K, Shivak DA, Yu Q, Li D, Pearl JR, Miller JC, Zhang L, Paschon DE, Hinkley SJ, Ankoudinova I, Lam S, Guschin D, Kopan L, Cherone JM, Nguyen HB, Qiao G, Ataei Y, Mendel MC, Amora R, Surosky R, Laganiere J, Vu BJ, Narayanan A, Sedaghat Y, Tillack K, Thiede C, Gärtner A, Kwak S, Bard J, Mrzljak L, Park L, Heikkinen T, Lehtimäki KK, Svedberg MM, Häggkvist J, Tari L, Tóth M, Varrone A, Halldin C, Kudwa AE, Ramboz S, Day M, Kondapalli J, Surmeier DJ, Urnov FD, Gregory PD, Rebar EJ, Muñoz-Sanjuán I, Zhang HS
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease
Park S, Colwell CS
Do disruptions in the circadian timing system contribute to autonomic dysfunction in Huntington's disease?
Evans AH, Okai D, Weintraub D, Lim SY, O’Sullivan SS, Voon V, Krack P, Sampaio C, Post B, Leentjens AFG, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A, IPMDS Rating Scales Review Committee
Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations
Huguet G, Temel Y, Kádár E, Pol S, Casaca-Carreira J, Segura-Torres P, Jahanshahi A
Altered expression of dopaminergic cell fate regulating genes prior to manifestation of symptoms in a transgenic rat model of Huntington's disease
Ochaba J, Fote G, Kachemov M, Thein S, Yeung SY, Lau AL, Hernandez S, Lim RG, Casale M, Neel MJ, Monuki ES, Reidling J, Housman DE, Thompson LM, Steffan JS
IKKβ slows Huntington's disease progression in R6/1 mice
Proc Natl Acad Sci USA
May 28, 2019
116 (22) :10952-10961
116 (22) :10952-10961
PMID: 31088970
Octeau JC, Gangwani MR, Allam SL, Tran D, Huang S, Hoang-Trong TM, Golshani P, Rumbell TH, Kozloski JR, Khakh BS
Transient, consequential increases in extracellular potassium ions accompany Channelrhodopsin2 excitation
Dvorzhak A, Helassa N, Török K, Schmitz D, Grantyna R
Single synapse indicators of impaired glutamate clearance derived from fast iGlu u imaging of cortical afferents in the striatum of normal and Huntington (Q175) mice
Svedberg MM, Varnäs K, Varrone A, Mitsios N, Mulder J, Gulyás B, Beaumont V, Munoz-Sanjuan I, Zaleska MM, Schmidt CJ, Halldin C, Mrzljak L
In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [(18)F] MNI-659
Holley SM, Galvan L, Kamdjou T, Dong A, Levine MS, Cepeda C
Major contribution of somatostatin-expressing interneurons and cannabinoid receptors to increased GABA synaptic activity in the striatum of Huntington's disease mice
Pido-Lopez J, Tanudjojo B, Farag S, Bondulich MK, Andre R, Tabrizi SJ, Bates GP
Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment
Sharma M, Subramaniam S
Rhes travels from cell to cell and transports Huntington disease protein via TNT-like protrusion
Shahn Z, Li Y, Sun Z, Mohan A, Sampaio C, Hu J
G-Computation and hierarchical models for estimating multiple causal effects from observational disease registries with irregular visits
Di Marco A, Gonzalez Paz O, Fini I, Vignone D, Cellucci A, Battista MR, Auciello G, Orsatti L, Zini M, Monteagudo E, Khetarpal V, Rose M, Dominguez C, Herbst T, Toledo-Sherman L, Summa V, Muñoz-Sanjuán I
Application of an in vitro blood-brain barrier model in the selection of experimental drug candidates for the treatment of Huntington's disease